Latest receivables for TARA: $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), TARA shows a receivables of $0. That compares with $890K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TARA's receivables is now $0 (was $890K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Protara Therapeutics is outperforming or lagging.
Tracking TARA's receivables over time shows whether Protara Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $890K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Protara Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.
Protara Therapeutics's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.